Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Immunotherapy is revolutionizing oncology by harnessing the power of the immune system to fight cancer...

ONCY : 0.9506 (-5.03%)
AUTL : 2.25 (-2.17%)
IOVA : 7.33 (-3.55%)
ABBV : 177.84 (-0.76%)
ONC.TO : 1.40 (-0.71%)
IBRX : 2.80 (+4.09%)
Autolus Therapeutics Presents Key Findings on obe-cel at the 2024 ASH Annual Meeting

Autolus Therapeutics presents data at ASH 2024 on obe-cel for adult relapsed/refractory B-ALL, highlighting clinical outcomes and cost efficiency.Quiver AI SummaryAutolus Therapeutics plc announced its...

AUTL : 2.25 (-2.17%)
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

AUTL : 2.25 (-2.17%)
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

AUTL : 2.25 (-2.17%)
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

AUTL : 2.25 (-2.17%)
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

AUTL : 2.25 (-2.17%)
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

AUTL : 2.25 (-2.17%)
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

AUTL : 2.25 (-2.17%)
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

AUTL : 2.25 (-2.17%)
Chart of the Day: Autolus Therapeutics - Effective Cancer Treatments

The Chart of the Day belongs to the oncology based biomedical company Autolus Therapeutics (AUTL) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

AUTL : 2.25 (-2.17%)

Barchart Exclusives

Is Rumble Stock a Buy, Sell, or Hold After a $775 Million Investment?
Rumble’s stock has shot up following an investment agreement with a giant crypto firm. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar